Navigation Links
Ventas to Present at Credit Suisse 2008 Global Real Estate Conference
Date:4/2/2008

LOUISVILLE, Ky., April 2, 2008 /PRNewswire-FirstCall/ -- Ventas, Inc. (NYSE: VTR) ("Ventas" or the "Company") said today that management will make a presentation regarding the Company at the Credit Suisse 2008 Global Real Estate Conference in New York on Wednesday, April 9, 2008 at 2:50 p.m. Eastern Time.

The presentation will be audio-webcast and may be accessed through the Company's website at http://www.ventasreit.com. Any written materials accompanying the presentation will also be available on the Company's website at the time of the presentation. The webcast and any written materials accompanying the presentation will be archived at http://www.ventasreit.com for 30 days.

Ventas, Inc. is a leading healthcare real estate investment trust. Its diverse portfolio of properties located in 43 states and two Canadian provinces includes seniors housing communities, skilled nursing facilities, hospitals and medical office and other properties. More information about Ventas can be found on its website at http://www.ventasreit.com.

Contacts: Debra A. Cafaro

Chairman, President and CEO

or

Richard A. Schweinhart

Executive Vice President and CFO

(502) 357-9000


'/>"/>
SOURCE Ventas, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
2. Ventas Board Names Ronald G. Geary Audit Committee Chair; Appoints Douglas Crocker II to Fill Vacancy on Audit Committee
3. Ventas Announces 2007 Third Quarter Earnings Release Date and Conference Call
4. Ventas Appoints Brush SVP - Senior Housing Development and Operations
5. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
6. Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance
7. Ventas Enters Agreement to Sell Common Stock
8. Ventas Completes Previously Announced Sale of Common Stock
9. Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69
10. Ventas to Present at the Citi 2008 Global Property CEO Conference
11. Ventas Appoints James D. Shelton and Robert D. Reed to Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...5 /PRNewswire-USNewswire/ -- As the general electi...Federation of Independent,Business ( http://www.nf...ates for a greater focus on the healthcare concern...epublican conventions are over, NFIB,is asking bot...tacles faced,by small businesses as they further d...
(Date:9/5/2008)...r risk prediction models are enhanced by taking in...NA repair capacity, according to research teams le... D. Anderson Cancer Center in two complementary pa...revention Research . , In the first study to foc...results based on increased exposure to certain ris...
(Date:9/4/2008)...a case-control study, the presence of measles viru...nd GI disturbances than in children with only GI d...nset were unrelated to MMR vaccine timing. Study ...y of Science on September 4 ( http://dx.plos.org/...mplementation of measles vaccines in 1963, three t...
(Date:9/4/2008)... Medelis, an oncology contract research organiz...nical Trials: A Nuanced Approach to Get Into the C...arry, a preclinical research scientist with 35 yea...al studies are commonly viewed as straightforward ...operate without true integration with preclinical,...
Breaking Medicine News(10 mins):Health News:Conventions Conclude, Fall Campaign Begins: NFIB Looks for More Focus on Small Business Healthcare Concerns 2Health News:Conventions Conclude, Fall Campaign Begins: NFIB Looks for More Focus on Small Business Healthcare Concerns 3Health News:Creating lung cancer risk models for specific populations refines prediction 2Health News:Creating lung cancer risk models for specific populations refines prediction 3Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 2Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3
...vered a potential new target, Akt2/PKB, a fat meta...er, PGC-1a for the treatment of type 2 diabetes. ...led by Morris J. Birnbaum at the University of Pen...icine. When a person eats, insulin is secreted by...
... to reel under a scorching June sun with most area...s Friday and Sri Ganganagar in Rajasthan at a sear... clouds were nowhere in sight. Following close b...as Amritsar in Punjab with a maximum of 46 degrees...
... conduct psychological tests on its recruits in a ...atricides that have occurred in the past few years...new tests (being introduced from October), we woul...f a recruit, his ability to grasp a given situatio...
...pitals Friday said that its recently launched Ches... and save lives of cardiac patients. The hospita...t week to address the need of preventing the loss ...e lives. Anil Maini, president, corporate develop...
Other Medicine News:Health News:Army to Conduct Psychological Tests During Recruits to Curb Suicides 2
(Date:9/5/2008)...t. 5 /- SARcode,Corporation...1 inhibitors,to treat inflammatory diseases, and S...announced SARcode,s initiation of a Phase 1 clinic...te for T-cell mediated ophthalmic,diseases. Sunesi...viding,SARcode with an exclusive license to Sunesi...
(Date:9/4/2008)...wswire-FirstCall/ -- BioForm Medical,Inc. (Nasdaq...l study of,Polidocanol, conducted in Germany by Bi...R & Co. GmbH (Kreussler), successfully met the stu...as part of a New Drug Application,(NDA) process., ...ficacy and safety of,Aethoxysklerol compared to So...
(Date:9/4/2008)...omen at More Than 100 Sites in the U.S., ANN ARBO...ticals, a,privately-held biopharmaceutical company...ompounds to treat endocrine, metabolic and,cardiov...tiated a second,Phase 3 clinical trial of Ophena(T...ee oral therapy in development for the treatment o...
(Date:9/4/2008)...dule with Two Abstracts Accepted for Presentat...008, BRIDGEWATER, N.J., Sept. 4 /- A...eutical company focused on the treatment of,cardio...e appointment of,Peter L. Garrambone, Jr. to the C...career includes more than 50 pharmaceutical,transa...
Breaking Medicine Technology:SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 4338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 5QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Inverted DNA turns quiet developmental gene into a potent driver of t cell lymphoma 12917 1Inverted DNA turns quiet developmental gene into a potent driver of t cell lymphoma 12917 2U of Minn researchers find primary alcohol prevention programs are needed for tweens 12914 1U of Minn researchers find primary alcohol prevention programs are needed for tweens 12914 2APIC Selected as Faculty in Blue Shield of California Foundation Initiative to Fight Healthcare Associated Infections 12910 1VA Has Added 20 New Vet Centers 12908 1VA Has Added 20 New Vet Centers 12908 2
...ording to the American Diabetes Association, the t...estimated to be $132 billion, or one out of every ... A chronic disease with no cure, diabetes is a gro...ational) marked by high levels of blood glucose re...n action, or both. Nearly 20 million Americans hav...
...Editor Harvard Medical School , ,With human i...n Asia and Eastern Europe, public health officials...lance, diagnosis, and treatment. The virus in que...s become epidemic in poultry and wild fowl in nume...ome humans in close contact with infected birds ha...
Other Medicine Technology:Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control 2Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control 3Avian (Bird) Flu: Is There a Role for Rapid Tests? 2Avian (Bird) Flu: Is There a Role for Rapid Tests? 3
7 mm blade, angled right. Flat handle.
1 mm diameter. Angled 33 degrees. Round handle.
3.5 mm blade. Round handle. Designated most popular model or size.
7 mm curved blade. Round handle.
Medicine Products: